1
|
Battista F, Muscas G, Parenti A, Spalletti M, Martinelli C, Carrai R, Amadori A, Della Puppa A. Intraoperative seizures during neuro-oncological supratentorial surgery: the role of prophylaxis with levetiracetam and intraoperative monitoring in a consecutive series of 353 patients. J Neurosurg Sci 2024:S0390-5616.24.06154-X. [PMID: 38563630 DOI: 10.23736/s0390-5616.24.06154-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
BACKGROUND The aim of this paper was to understand the role of prophylaxis with levetiracetam at skin incision in preventing convulsive intraoperative seizures (IOS) during neurosurgical procedures with and without intraoperative neuromonitoring (IONM). METHODS Authors retrospectively reviewed the Institutional database for cases of supratentorial brain tumors undergoing surgical resection performed from January 2021 to October 2022. Patients were operated on both under general anesthesia and awake, using motor-evoked potentials (MEP) and direct cortical stimulation for cortical mapping. 1000 mg ev of Levetiracetam before skin incision in case of a history of seizures was administrated. We excluded all infratentorial cases. RESULTS Three hundred fisty three consecutive cases were retrieved. IOS occurred in 22 patients (6.2%). Prophylaxis with Levetiracetam was administered in 149 patients, and IOS occurred in 16 cases (10.7%) in this group of patients. The IOS rate in the case of no Levetiracetam prophylaxis administration (3.5%) was significantly lower (P<0.001, OR=3.38 [1.35-8.45], RR=3.12 [1.32-7.41]). The Penfield technique stimulation evoked seven of all 22 IOS reported (31.8%) (P=0.006, RR 5.4 [1.44 -20.58], OR 21 [2.3-183.9]), and the train-of-five technique stimulation caused two of all registered IOS (8.7%) (P=0.2, RR 2.3 [0.99-5.67], OR 6.5 [0.55-76.17]). Transcranial MEPs evoked no IOS. CONCLUSIONS Under levetiracetam prophylaxis, the IOS rate was not significantly lower than in the group of patients without Levetiracetam prophylaxis, regardless of the histology of the tumor and IONM. Neither the transcranial stimulation (MEP) nor train-of-five technique stimulation increases the risk of convulsive IOS, as Penfield technique stimulation does.
Collapse
Affiliation(s)
- Francesca Battista
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), Careggi University Hospital, University of Florence, Florence, Italy -
| | - Giovanni Muscas
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), Careggi University Hospital, University of Florence, Florence, Italy
| | - Alberto Parenti
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), Careggi University Hospital, University of Florence, Florence, Italy
| | - Maddalena Spalletti
- Unit of Neurophysiology, Department of Neuro-Muscular-Skeletal, Careggi University Hospital, University of Florence, Florence, Italy
| | - Cristiana Martinelli
- Unit of Neurophysiology, Department of Neuro-Muscular-Skeletal, Careggi University Hospital, University of Florence, Florence, Italy
| | - Riccardo Carrai
- Unit of Neurophysiology, Department of Neuro-Muscular-Skeletal, Careggi University Hospital, University of Florence, Florence, Italy
| | - Andrea Amadori
- Neuro-Anesthesiology and Intensive Care Unit, Careggi University Hospital, University of Florence, Florence, Italy
| | - Alessandro Della Puppa
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Drug Area and Child Health (NEUROFARBA), Careggi University Hospital, University of Florence, Florence, Italy
| |
Collapse
|
2
|
Biagetti C, Tatarelli P, Tebano G, Casolari S, Fantini M, Malavolti M, Amadori A, Tura GA, Sambri V, Minghetti M, Grilli R, Gagliotti C. Containment of carbapenem-resistant Enterobacterales colonisations and infections: Results from an integrated infection control intervention in a large hospital trust of northern Italy. Am J Infect Control 2024; 52:66-72. [PMID: 37543306 DOI: 10.1016/j.ajic.2023.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 07/27/2023] [Accepted: 07/28/2023] [Indexed: 08/07/2023]
Abstract
PURPOSE We describe the results of an infection control intervention, implemented in 4 tertiary hospitals in Romagna, Italy, aiming at containing the spread of carbapenem-resistant Enterobacterales (CRE). METHODS The intervention consisted of rectal screening in patients at risk for CRE; pre-emptive contact precaution waiting for screening results; timely notification of CRE identification and concomitant computerized alert; contact precaution for confirmed CRE-positive patients. We performed an interrupted time series analysis to compare the incidence of CRE bacteraemia, of other CRE infections, and CRE-positive rectal swabs in the pre and postintervention period (January 2015-July 2017 and August 2017-June 2020, respectively). RESULTS 4,332 CRE isolates were collected. Klebsiella pneumoniae was the most represented pathogen (n = 3,716, 85%); KPC production was the most common resistance mechanism (n = 3,896, 90%). The incidence rate of CRE bacteraemia significantly decreased from 0.554 to 0.447 episodes per 10.000 patient days in the early postintervention period (P = .001). The incidence rate of other CRE infections significantly decreased from 2.09 to 1.49 isolations per 10.000 patient days in the early postintervention period (P = .021). The monthly number of rectal swabs doubled in the postintervention period and there was a significant reduction trend of CRE-positive swabs, sustained over time (P < .001). CONCLUSIONS The infection control intervention was successful in containing the spread of CRE infections and colonisations.
Collapse
Affiliation(s)
- C Biagetti
- Division of Infectious diseases, Infermi Hospital, Rimini, AUSL Romagna, Italy
| | - P Tatarelli
- Division of Infectious diseases, Santa Maria delle Croci Hospital, Ravenna, AUSL Romagna, Italy.
| | - G Tebano
- Division of Infectious diseases, Santa Maria delle Croci Hospital, Ravenna, AUSL Romagna, Italy
| | - S Casolari
- Division of Infectious diseases, Santa Maria delle Croci Hospital, Ravenna, AUSL Romagna, Italy
| | - M Fantini
- U.O. Ricerca Valutativa e Policy Servizi Sanitari AUSL Romagna, Italy
| | - M Malavolti
- Hospital Direction, Santa Maria delle Croci Hospital, Ravenna, AUSL Romagna, Italy
| | - A Amadori
- Hospital Direction, G.B. Morgagni-L. Pierantoni Hospital, Forlì, AUSL Romagna, Italy
| | - G A Tura
- Hospital Direction, Infermi Hospital, Rimini, AUSL Romagna, Italy
| | - V Sambri
- Microbiologia AUSL della Romagna, Cesena, Italy
| | - M Minghetti
- Hospital Direction, M. Bufalini Hospital, Cesena, Italy
| | - R Grilli
- U.O. Ricerca Valutativa e Policy Servizi Sanitari AUSL Romagna, Italy
| | - C Gagliotti
- Agenzia Sanitaria e Sociale Regionale-Regione Emilia-Romagna, Bologna, Italy
| |
Collapse
|
3
|
Carrai R, Morone F, Baldanzi F, Martinelli C, Bonaudo C, Tola S, Muscas G, Caramelli R, Spalletti M, Grippo A, Bucciardini L, Amadori A, Della Puppa A. Intraoperative Mapping of the Sensory Root of the Trigeminal Nerve in Patients with Pontocerebellar Angle Pathology. World Neurosurg 2023; 178:e104-e112. [PMID: 37454910 DOI: 10.1016/j.wneu.2023.06.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 06/30/2023] [Indexed: 07/18/2023]
Abstract
OBJECTIVE The aim of the present study was to determine the position of the 3 sensory branches of the trigeminal nerve in the preganglionic tract using intraoperative neurophysiological mapping. METHODS We included consecutive adult patients who underwent neurosurgical treatment of cerebellopontine angle lesions. The trigeminal nerve was antidromically stimulated at 3 sites along its circumference with different stimulus intensities at a distance of ≤1 cm from the brainstem. The sensory nerve action potentials (SNAPs) were recorded from each main trigeminal branch (V1 [ophthalmic branch], V2 [maxillary branch], and V3 [mandibular branch]). RESULTS We analyzed 13 patients. The stimulation points at which we obtained the greatest number of congruous and exclusive SNAPs (SNAPs only on the stimulated branch) was the stimulation point for V3 (20.7%). The stimulation intensity at which we obtained the highest number of congruent and exclusive SNAPs with the stimulated branch was 0.5 mA. CONCLUSIONS Using our recording conditions, trigeminal stimulation is a reliable technique for mapping the V3 and V1 branches using an intensity not exceeding 0.5. However, reliable identification of the fibers of V2 is more difficult. Stimulation of the trigeminal nerve can be a reliable technique to identify the V3 and V1 branches if rhizotomy of these branches is necessary.
Collapse
Affiliation(s)
- Riccardo Carrai
- SODc Neurophysiopathology, AOU Careggi, University Hospital, Florence, Italy
| | - Francesca Morone
- Neurosurgery Unit, Head and Neck Department, AORN San G. Moscati Hospital, Avellino, Italy
| | - Fabrizio Baldanzi
- SODc Neurophysiopathology, AOU Careggi, University Hospital, Florence, Italy
| | | | - Camilla Bonaudo
- Neurosurgery Clinic, AOU Careggi University Hospital, Florence, Italy
| | - Serena Tola
- Neurosurgery Clinic, AOU Careggi University Hospital, Florence, Italy
| | - Giovanni Muscas
- Neurosurgery Clinic, AOU Careggi University Hospital, Florence, Italy
| | - Riccardo Caramelli
- SODc Neurophysiopathology, AOU Careggi, University Hospital, Florence, Italy
| | - Maddalena Spalletti
- SODc Neurophysiopathology, AOU Careggi, University Hospital, Florence, Italy
| | - Antonello Grippo
- SODc Neurophysiopathology, AOU Careggi, University Hospital, Florence, Italy.
| | - Luca Bucciardini
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| | - Andrea Amadori
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| | | |
Collapse
|
4
|
Carrai R, Martinelli C, Baldanzi F, Gabbanini S, Bonaudo C, Pedone A, Federico C, Caramelli R, Spalletti M, Lolli F, Grippo A, Bucciardini L, Della Puppa A, Ninone TA, Amadori A. Is the Patient State Index a reliable parameter as guide to anaesthesiology in cranial neurosurgery? A first intraoperative study and a literature review. Neurophysiol Clin 2023; 53:102910. [PMID: 37926053 DOI: 10.1016/j.neucli.2023.102910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 09/29/2023] [Accepted: 10/11/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Patient State Index (PSI) and Suppression Ratio (SR) are two indices calculated by quantitative analysis of EEG used to estimate the depth of anaesthesia but their validation in neurosurgery must be done. Our aim was to investigate the congruity PSI and SR with raw EEG monitoring in neurosurgery. METHODS We included 34 patients undergoing elective cranial neurosurgery. Each patient was monitored by a SedLine device (PSI and SR) and by raw EEG. To appraise the agreement between PSI, SR and EEG Suppr%, Bland-Altman analysis was used. We also correlated the PSI and SR recorded at different times during surgery to the degree of suppression of the raw EEG data by Spearman's rank correlation coefficient. For a comparison with previous data we made an international literature review according to PRISMA protocol. RESULTS At all recording times, we found that there is a strong agreement between PSI and raw EEG. We also found a significant correlation for both PSI and SR with the EEG suppression percentage (p < 0.05), but with a broad dispersion of the individual values within the confidence interval. CONCLUSION The Masimo SedLine processed EEG monitoring system can be used as a guide in the anaesthetic management of patients during elective cranial neurosurgery, but the anaesthesiologist must be aware that previous correlations between PSI and SR with the suppression percentage may not always be valid in all individual patients. The use of an extended visual raw EEG evaluated by an expert electroencephalographer might help to provide better guidance.
Collapse
Affiliation(s)
- Riccardo Carrai
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Cristiana Martinelli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Fabrizio Baldanzi
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Simonetta Gabbanini
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Camilla Bonaudo
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Agnese Pedone
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Capelli Federico
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Riccardo Caramelli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Maddalena Spalletti
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Francesco Lolli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy
| | - Antonello Grippo
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, University Hospital, Florence, Italy.
| | - Luca Bucciardini
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| | - Alessandro Della Puppa
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | | | - Andrea Amadori
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| |
Collapse
|
5
|
Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, Amadori A, Rosati M, Stefanetti M, Burgio SL, Cursano MC, Lolli C, Zampiga V, Cangini I, Schepisi G, De Giorgi U. Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients. Front Oncol 2023; 13:1221096. [PMID: 37664032 PMCID: PMC10468566 DOI: 10.3389/fonc.2023.1221096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 07/28/2023] [Indexed: 09/05/2023] Open
Abstract
Introduction Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes. Methods We conducted a multicenter retrospective cohort study of advanced (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) OC treated between 2014 and 2018 to assess progression-free survival (PFS) and overall survival (OS) in relation to TTC. All patients underwent a germline multigene panel for BRCA1/2 evaluation. Results Among the 83 patients who underwent PDS, a TTC ≥ 60 days was associated with a shorter PFS (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.04-3.93, p = 0.038), although this association lost statistical significance when adjusting for residual disease (HR 1.52, 95% CI 0.75-3.06, p = 0.244, for TTC and HR 2.73, 95% CI 1.50-4.96, p = 0.001, for residual disease). Among 52 IDS patients, we found no evidence of an association between TTC and clinical outcomes. Ascites, type of chemotherapy, or germline BRCA1/2 mutational status did not influence TTC and were not associated with clinical outcomes in PDS or IDS patients. Discussion In conclusion, longer TTC seems to negatively affect prognosis in patients undergoing PDS, especially those with residual disease.
Collapse
Affiliation(s)
- Alberto Farolfi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Elisabetta Petracci
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Giorgia Gurioli
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Gianluca Tedaldi
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Claudia Casanova
- Oncology Department, Santa Maria delle Croci Hospital, Ravenna, Italy
| | - Valentina Arcangeli
- Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Andrea Amadori
- Department of Gynaecology and Obstetrics, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Marta Rosati
- Department of Medical Oncology, Infermi Hospital, Rimini, Italy
| | - Marco Stefanetti
- Department of Gynaecology and Obstetrics, Infermi Hospital, Rimini, Italy
| | - Salvatore Luca Burgio
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Maria Concetta Cursano
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Cristian Lolli
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Valentina Zampiga
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Ilaria Cangini
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Giuseppe Schepisi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| | - Ugo De Giorgi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
| |
Collapse
|
6
|
Giannella L, Delli Carpini G, Di Giuseppe J, Bogani G, Sopracordevole F, Clemente N, Giorda G, De Vincenzo RP, Evangelista MT, Gardella B, Dominoni M, Monti E, Alessi C, Alessandrini L, Pagan A, Caretto M, Ghelardi A, Amadori A, Origoni M, Barbero M, Raspagliesi F, Simoncini T, Vercellini P, Scambia G, Ciavattini A. In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group). Cancers (Basel) 2023; 15:cancers15112876. [PMID: 37296839 DOI: 10.3390/cancers15112876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/09/2023] [Accepted: 05/22/2023] [Indexed: 06/12/2023] Open
Abstract
It is unknown whether human papillomavirus (HPV) status impacts the prognosis of early stage cervical glandular lesions. This study assessed the recurrence and survival rates of in situ/microinvasive adenocarcinomas (AC) according to HPV status during a 5-year follow-up. The data were retrospectively analyzed in women with available HPV testing before treatment. One hundred and forty-eight consecutive women were analyzed. The number of HPV-negative cases was 24 (16.2%). The survival rate was 100% in all participants. The recurrence rate was 7.4% (11 cases, including four invasive lesions (2.7%)). Cox proportional hazards regression showed no difference in recurrence rate between HPV-positive and HPV-negative cases (p = 0.148). HPV genotyping, available for 76 women and including 9/11 recurrences, showed a higher relapse rate for HPV-18 than HPV-45 and HPV-16 (28.5%, 16.6%, and 9.52%, p = 0.046). In addition, 60% and 75% of in situ and invasive recurrences, respectively, were HPV-18 related. The present study showed that most ACs were positive for high-risk HPV, and the recurrence rate was unaffected by HPV status. More extensive studies could help evaluate whether HPV genotyping may be considered for recurrence risk stratification in HPV-positive cases.
Collapse
Affiliation(s)
- Luca Giannella
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, 60123 Ancona, Italy
| | - Giovanni Delli Carpini
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, 60123 Ancona, Italy
| | - Jacopo Di Giuseppe
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, 60123 Ancona, Italy
| | - Giorgio Bogani
- Gynecological Oncology Unit, Fondazione IRCCS-Istituto Nazionale Tumori, 20133 Milan, Italy
| | - Francesco Sopracordevole
- Gynecologic Oncology Unit, IRCCS-Centro di Riferimento Oncologico di Aviano, 33081 Aviano, Italy
| | - Nicolò Clemente
- Gynecologic Oncology Unit, IRCCS-Centro di Riferimento Oncologico di Aviano, 33081 Aviano, Italy
| | - Giorgio Giorda
- Gynecologic Oncology Unit, IRCCS-Centro di Riferimento Oncologico di Aviano, 33081 Aviano, Italy
| | - Rosa Pasqualina De Vincenzo
- Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Dipartimento di Scienze della Vita e Sanita Pubblica, Università Cattolica Del Sacro Cuore, 00168 Rome, Italy
| | - Maria Teresa Evangelista
- Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
| | - Barbara Gardella
- Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, 27100 Pavia, Italy
| | - Mattia Dominoni
- Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, 27100 Pavia, Italy
| | - Ermelinda Monti
- Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
| | - Chiara Alessi
- UOC Ostetricia Ginecologia, Dipartimento per la Salute della Donna e del Bambino, Azienda Ospedaliera-Università di Padova, 35128 Padova, Italy
| | - Lara Alessandrini
- Pathological Anatomy Unit, Department of Medicine DIMED, University of Padova, 35128 Padova, Italy
| | | | - Marta Caretto
- Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
| | - Alessandro Ghelardi
- Azienda Usl Toscana Nord-Ovest, UOC Ostetricia e Ginecologia, Ospedale Apuane, 54100 Massa, Italy
| | | | - Massimo Origoni
- Department of Gynecology & Obstetrics, Vita Salute San Raffaele University School of Medicine, 20132 Milan, Italy
| | - Maggiorino Barbero
- Department of Obstetrics and Gynecology, Asti Community Hospital, 14100 Asti, Italy
| | - Francesco Raspagliesi
- Gynecological Oncology Unit, Fondazione IRCCS-Istituto Nazionale Tumori, 20133 Milan, Italy
| | - Tommaso Simoncini
- Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
| | - Paolo Vercellini
- Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
| | - Giovanni Scambia
- Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Dipartimento di Scienze della Vita e Sanita Pubblica, Università Cattolica Del Sacro Cuore, 00168 Rome, Italy
| | - Andrea Ciavattini
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, 60123 Ancona, Italy
| |
Collapse
|
7
|
Carrai R, Martinelli C, Baldanzi F, Gabbanini S, Gori B, Masi G, Troiano S, Bonaudo C, Esposito A, Muscas G, Tola S, Caramelli R, Spalletti M, Lolli F, Grippo A, Bucciardini L, Amadori A, Della Puppa A. Feasibility of Intraoperative Visual Evoked Potential Monitoring by Cortical Strip Electrodes in Patients During Brain Surgery: A Preliminary Study. World Neurosurg 2023; 171:175-180.e0. [PMID: 36521757 DOI: 10.1016/j.wneu.2022.12.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Revised: 12/06/2022] [Accepted: 12/07/2022] [Indexed: 12/14/2022]
Abstract
OBJECTIVE The role of visual evoked potentials (VEPs) monitoring during neurosurgical procedure in patient remains unclear. The purpose of our study was to determine the feasibility of intraoperative VEP recording using a strip cortical electrode during surgical resection of intracranial lesions. METHODS In this prospective, monocentric, observational study, we enrolled consecutive patients undergoing neurosurgical procedure for intracranial lesions. After dural opening, a cortical strip was positioned on the lateral occipital surface. Flash VEPs were continuously recorded using both subdermal corkscrew electrodes and strip electrodes. An electroretinogram was also recorded to guarantee delivery of adequate flash stimuli to the retina. RESULTS We included 10 patients affected by different intracranial lesions. Flash VEPs were recorded using subdermal corkscrew electrodes in all patients except 1 in whom they were never identified during the recording. Flash VEPs were recorded using strip electrodes in all patients and showed a polyphasic morphology with a significantly larger amplitude compared with that of flash VEPs measured using subdermal corkscrew electrodes. No patient reported worsened postoperative vision and a >50% decrease in the VEPs amplitude was never registered. CONCLUSIONS We have reported for the first time in the literature that VEP monitoring during a neurosurgical procedure is feasible via a cortical strip located on the occipital surface. The technique demonstrated greater stability and a larger amplitude compared with recordings with scalp electrodes, facilitating identification of any changes. Studies with more patients are needed to assess the clinical reliability of the technique.
Collapse
Affiliation(s)
- Riccardo Carrai
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy.
| | - Cristiana Martinelli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Fabrizio Baldanzi
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Simonetta Gabbanini
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Benedetta Gori
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Giulia Masi
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Simone Troiano
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Camilla Bonaudo
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Alice Esposito
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Giovanni Muscas
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Serena Tola
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| | - Riccardo Caramelli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Maddalena Spalletti
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Francesco Lolli
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Antonello Grippo
- SODc Neurophysiopathology, Department Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi University Hospital, Florence, Italy
| | - Luca Bucciardini
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| | - Andrea Amadori
- Neuro-Anesthesiology and Intensive Care Unit, AOU Careggi University Hospital, Florence, Italy
| | - Alessandro Della Puppa
- Neurosurgery Clinic, Department of Neuroscience, Psychology, Pharmacology and Child Health, AOU Careggi University Hospital, Florence, Italy
| |
Collapse
|
8
|
Delli Carpini G, Giorgi Rossi P, Giannella L, Di Giuseppe J, Clemente N, Sopracordevole F, Barbero M, Bogani G, De Vincenzo R, Origoni M, Cantatore F, Gardella B, Dominoni M, Monti E, Liverani CA, Viscardi A, Pagan A, Amadori A, Alessi C, Andolfatto M, Cattani P, Pieralli A, Stevenazzi G, Ciavattini A. Monitoring the activities of Italian colposcopy clinics before and during the COVID-19 pandemic. J Gynecol Oncol 2023; 34:e7. [PMID: 36245226 DOI: 10.3802/jgo.2023.34.e7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 07/18/2022] [Accepted: 08/29/2022] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVE To evaluate the impact of healthcare reorganization during the severe acute respiratory syndrome coronavirus 2 pandemic on Italian colposcopy clinic activities, focusing on cervical excision procedures, follow-ups for conservative management of low-grade lesions, and follow-ups post cervical excision. METHODS Retrospective study conducted in 14 Italian colposcopy clinics. The number and clinical characteristics of cervical excisions, follow-ups for conservative management of low-grade lesions, and follow-ups after cervical excision were compared between the period March 1, 2019 to February 29, 2020 (pre-pandemic) and March 1, 2020 to February 28, 2021 (pandemic) with a Poisson regression analysis. RESULTS In the pandemic period, the number of cervical excisions was reduced by 8.8% (95% confidence interval [CI]=-15.6% to -2%; p=0.011). Excisions were less frequently performed in the operating room (-35.1%; 95% CI=-47.6% to -22.6%; p<0.001), the number of patients from spontaneous screening was reduced by -14.0% (95% CI=-23.4% to -4.6%; p=0.003), and the CO2-laser technique was used less frequently (-30%; 95% CI=-45.1% to -15.0%; p<0.001). As compared to the pre-pandemic period, the number of follow-ups for conservative management of low-grade lesions was reduced by -26.7% (95% CI=-39.0% to -14.4%; p<0.001), and the follow-up appointments after cervical excision were reduced by -51.0% (95% CI=-58.1% to -43.9%; p<0.001). CONCLUSION The most significant impact of the healthcare reorganization during the coronavirus disease 2019 pandemic was on follow-ups after cervical excision. The resumption of disrupted activities should follow a risk-based prioritization, starting from women in follow-up after cervical excision. It is advisable that the trend of performing cervical excision as an outpatient procedure is maintained in the post-pandemic period.
Collapse
Affiliation(s)
- Giovanni Delli Carpini
- Gynecology Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy
| | - Paolo Giorgi Rossi
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Luca Giannella
- Gynecology Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy
| | - Jacopo Di Giuseppe
- Gynecology Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy
| | - Nicolò Clemente
- Gynecological Oncology Unit, Centro di Riferimento Oncologico-National Cancer Institute, Aviano, Italy
| | - Francesco Sopracordevole
- Gynecological Oncology Unit, Centro di Riferimento Oncologico-National Cancer Institute, Aviano, Italy
| | - Maggiorino Barbero
- Department of Obstetrics and Gynecology, Asti Community Hospital, Asti, Italy
| | - Giorgio Bogani
- Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Rosa De Vincenzo
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.,Dipartimento di Scienze della vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Massimo Origoni
- Department of Gynecology & Obstetrics, Vita Salute San Raffaele University School of Medicine, Milan, Italy
| | - Francesco Cantatore
- Department of Gynecology & Obstetrics, Vita Salute San Raffaele University School of Medicine, Milan, Italy
| | | | | | - Ermelinda Monti
- Gynecology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
| | - Carlo Antonio Liverani
- Gynecology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
| | - Anna Viscardi
- Gynecology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
| | | | | | - Chiara Alessi
- UOC Ostetricia Ginecologia, Dipartimento per la Salute della Donna e del Bambino, Azienda Ospedaliera - Università di Padova, Padova, Italy
| | - Matteo Andolfatto
- UOC Ostetricia Ginecologia, Dipartimento per la Salute della Donna e del Bambino, Azienda Ospedaliera - Università di Padova, Padova, Italy
| | - Paolo Cattani
- Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV), Rome, Italy
| | - Annalisa Pieralli
- Department of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and Gynecology, University of Florence, Florence, Italy
| | - Guido Stevenazzi
- Department of Obstetrics and Gynaecology, ASST OVEST MI, Legnano (Milan) Hospital, Legnano, Italy
| | - Andrea Ciavattini
- Gynecology Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy.
| |
Collapse
|
9
|
Bonaudo C, Orlandini S, Boschi A, Martinelli C, Carrai R, Amadori A, Della Puppa A. Surgery of optic-chiasmatic tumors assisted by sodium fluorescein yellow fluorescence and visual evoked potentials monitoring. J Neurosurg Sci 2022:S0390-5616.22.05888-X. [PMID: 36327110 DOI: 10.23736/s0390-5616.22.05888-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2024]
Abstract
BACKGROUND Tumours of the anterior visual pathways are challenging to operate because of the crucial balance between extent of resection and sight preservation. Sodium Fluoresceine (SF) has already been reported in maximizing brain tumour resection but not when the optic-chiasmatic region is involved. The role of Visual Evoked Potentials (VEPs) in optic-chiasmatic tumours is still debated. The simultaneous use of both technique in this setting has not been reported so far. The aim of our work is to analyse the intraoperative combination of the use of SF and VEPs in the anterior visual pathway tumour surgery. METHODS Clinical and Intra-operative data from six surgical procedures on four patients affected by optic-chiasmatic tumours with preoperative visual deficits were retrospectively analysed. RESULTS In 5 procedures VEPs remained intraoperatively stable and no postoperative worsening of visual function was reported. In 1 case an intraoperative VEPs deterioration was predictive of a postoperative visual worsening. In all cases, tumour was fluorescent, and SF was intraoperatively helpful in guiding resection. The pattern of fluorescence was different according to the lesion histology. CONCLUSIONS Based on our preliminary experience, the simultaneous combination of SF and VEPs in surgery of the optic pathway tumours seems helpful to maximize tumour resection and predict postoperative functional outcome. Since we presented a small series, larger studies are needed to confirm our data.
Collapse
Affiliation(s)
- Camilla Bonaudo
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Pharmacology and Child Health, University Hospital of Careggi, University of Florence, Florence, Italy -
| | - Simone Orlandini
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Pharmacology and Child Health, University Hospital of Careggi, University of Florence, Florence, Italy
| | - Andrea Boschi
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Pharmacology and Child Health, University Hospital of Careggi, University of Florence, Florence, Italy
| | - Cristiana Martinelli
- Department of Neurophysiopathology, University Hospital of Careggi, Florence, Italy
| | - Riccardo Carrai
- Department of Neurophysiopathology, University Hospital of Careggi, Florence, Italy
| | - Andrea Amadori
- Intensive Care Unit, Department of Neuroanaesthesia, University Hospital of Careggi, Florence, Italy
| | - Alessandro Della Puppa
- Unit of Neurosurgery, Department of Neuroscience, Psychology, Pharmacology and Child Health, University Hospital of Careggi, University of Florence, Florence, Italy
| |
Collapse
|
10
|
Carneiro RK, Gatti GT, Beck RC, Amadori A, Oliveira TD, Feliciano MAR, Alievi MM, Ferreira MP. Musladin-Lueke Syndrome in a Dog: Case Report. Top Companion Anim Med 2022; 51:100694. [PMID: 35850448 DOI: 10.1016/j.tcam.2022.100694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 07/05/2022] [Accepted: 07/11/2022] [Indexed: 12/14/2022]
Abstract
The aim of this study is to report the case of a 4-month-old Beagle dog diagnosed with Musladin-Lueke syndrome. The dog appeared to walk on the digits ("tiptoes") with all limbs during ambulation and rigid extension of the carpus, elbow, tarsus, and knee joints during ambulation. Thickening of the fur and auricular cartilage, reduction in radiocarpal, and tibiotarsal joint amplitude, macrocephaly, and lateralized eyes were noticed on physical examination. Echocardiography showed reduced mobility and altered (tortuous) valve morphology. Bilateral abdominal cryptorchidism was confirmed by ultrasonography. Musladin-Lueke syndrome was the presumptive diagnosis, based on the clinical signs presented. The diagnosis was confirmed after DNA testing performed by serial collection of saliva. This is the first paper that describes unprecedented cardiac and reproductive changes of Musladin-Lueke syndrome in which the dog was followed for 2 years, presenting a good quality of life.
Collapse
Affiliation(s)
- R K Carneiro
- Department of Veterinary Surgery, UNESP, Jaboticabal, SP, Brazil
| | - G T Gatti
- Department of Diagnostic Imaging, UFRGS, Porto Alegre, RS, Brazil
| | - R C Beck
- Department of Anesthesiology, UFRGS, Porto Alegre, RS, Brazil
| | - A Amadori
- Department of Diagnostic Imaging, UFRGS, Porto Alegre, RS, Brazil
| | - T D Oliveira
- Department of Anesthesiology, UFRGS, Porto Alegre, RS, Brazil
| | - M A R Feliciano
- Department of Large Animal Clinic, UFSM, Santa Maria, RS, Brazil
| | - M M Alievi
- Department of Animal Medicine, UFRGS, Porto Alegre, RS, Brazil
| | - M P Ferreira
- Department of Animal Medicine, UFRGS, Porto Alegre, RS, Brazil.
| |
Collapse
|
11
|
Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A, Betella I, Grassi T, Bianchi T, Di Martino G, Amadori A, Maniglio P, Strada I, Carinelli S, Jaconi M, Aletti G, Zanagnolo V, Maggioni A, Savelli L, De Giorgi U, Landoni F, Colombo N, Fruscio R. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Front Oncol 2022; 12:970918. [PMID: 36237308 PMCID: PMC9551309 DOI: 10.3389/fonc.2022.970918] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 09/05/2022] [Indexed: 11/13/2022] Open
Abstract
Simple summaryLow-grade serous ovarian cancer (LGSOC) represents an uncommon histotype of serous ovarian cancer (accounting for approximately 5% of all ovarian cancer) with a distinct behavior compared to its high-grade serous counterpart, characterized by a better prognosis and low response rate to chemotherapeutic agents. Similar to high-grade serous ovarian cancer, cytoreductive surgery is considered crucial for patient survival. This retrospective study aimed to analyze the outcomes of women affected by advanced stages (III–IV FIGO) of LGSOC from two high-volume oncological centers for ovarian neoplasm. In particular, we sought to evaluate the impact on survival outcomes of optimal cytoreductive surgery [i.e., residual disease (RD) <10 mm at the end of surgery]. The results of our work confirm the role of complete cytoreduction (i.e., no evidence of disease after surgery) in the survival of patients and even the positive prognostic role of a minimal RD (i.e., <10 mm), whenever complete cytoreduction cannot be achieved.BackgroundLow-grade serous ovarian cancer (LGSOC) is a rare entity with different behavior compared to high-grade serous (HGSOC). Because of its general low chemosensitivity, complete cytoreductive surgery with no residual disease is crucial in advanced stage LGSOC. We evaluated the impact of optimal cytoreduction on survival outcome both at first diagnosis and at recurrence.MethodsWe retrospectively studied consecutive patients diagnosed with advanced LGSOCs who underwent cytoreductive surgery in two oncological centers from January 1994 to December 2018. Survival curves were estimated by the Kaplan–Meier method, and 95% confidence intervals (95% CI) were estimated using the Greenwood formula.ResultsA total of 92 patients were included (median age was 47 years, IQR 35–64). The median overall survival (OS) was 142.3 months in patients with no residual disease (RD), 86.4 months for RD 1–10 mm and 35.2 months for RD >10 mm (p = 0.002). Progression-free survival (PFS) was inversely related to RD after primary cytoreductive surgery (RD = 0 vs RD = 1–10 mm vs RD >10 mm, p = 0.002). On multivariate analysis, RD 1–10 mm (HR = 2.30, 95% CI 1.30–4.06, p = 0.004), RD >10 mm (HR = 3.89, 95% CI 1.92–7.88, p = 0.0004), FIGO stage IV (p = 0.001), and neoadjuvant chemotherapy (NACT) (p = 0.010) were independent predictors of PFS. RD >10 mm (HR = 3.13, 95% CI 1.52–6.46, p = 0.004), FIGO stage IV (p <0.0001) and NACT (p = 0.030) were significantly associated with a lower OS.ConclusionsOptimal cytoreductive surgery improves survival outcomes in advanced stage LGSOCs. When complete debulking is impossible, a RD <10 mm confers better OS compared to an RD >10 mm in this setting of patients.
Collapse
Affiliation(s)
- Paolo Di Lorenzo
- Obstetrics and Gynecology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
- *Correspondence: Paolo Di Lorenzo, ; Ugo De Giorgi,
| | - Vincenza Conteduca
- Department of Medical Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy
- Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy
| | - Emanuela Scarpi
- Biostatistics and Clinical Trials Unit, Istituto di ricovero e cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy
| | - Marco Adorni
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Francesco Multinu
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Annalisa Garbi
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Ilaria Betella
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Tommaso Grassi
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Tommaso Bianchi
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Giampaolo Di Martino
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Andrea Amadori
- Obstetrics and Gynecology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Paolo Maniglio
- Obstetrics and Gynecology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Isabella Strada
- Obstetrics and Gynecology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Silvestro Carinelli
- Department of Pathology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Marta Jaconi
- Department of Pathology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Giovanni Aletti
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
- Department of Hemato-Oncology, University of Milan, Milano, Italy
| | - Vanna Zanagnolo
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Angelo Maggioni
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
| | - Luca Savelli
- Obstetrics and Gynecology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Ugo De Giorgi
- Department of Medical Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy
- *Correspondence: Paolo Di Lorenzo, ; Ugo De Giorgi,
| | - Fabio Landoni
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
| | - Nicoletta Colombo
- Division of Gynecologic Oncology, European Institute of Oncology, Istituto di ricovero e cura a carattere scientifico (IRCCS), Milano, Italy
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
| | - Robert Fruscio
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
| |
Collapse
|
12
|
Domeniconi L, Amadori A, Maniglio P, Saragoni L. Atypical polypoid adenomyoma of the endometrium: diagnosis and treatment. A case report. Pathologica 2020; 112:214-218. [PMID: 33393525 PMCID: PMC8183343 DOI: 10.32074/1591-951x-112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 06/29/2020] [Indexed: 11/30/2022] Open
Abstract
Atypical polypoid adenomyoma (APA) is a rare uterine lesion that commonly recurs after local excision and is occasionally associated with or anticipates the development of atypical hyperplasia or endometrioid adenocarcinoma. We report a case of a 45-year-old woman affected by APA treated with local resection.
Collapse
Affiliation(s)
| | - Andrea Amadori
- Gynecology Unit, G.B. Morgagni-L. Pierantoni Hospital, Forlì, Italy
| | - Paolo Maniglio
- Gynecology Unit, G.B. Morgagni-L. Pierantoni Hospital, Forlì, Italy
| | - Luca Saragoni
- Department of Pathology, G.B. Morgagni-L. Pierantoni Hospital, Forlì, Italy
| |
Collapse
|
13
|
Limbucci N, Cirelli C, Valente I, Nappini S, Renieri L, Laiso A, Rosi A, Amadori T, Amadori A, Mangiafico S. Y-Stenting Versus PulseRider-Assisted Coiling in the Treatment of Wide-Neck Bifurcation Aneurysms: Role of Anatomical Features on Midterm Results. Neurosurgery 2019; 87:329-337. [DOI: 10.1093/neuros/nyz490] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 09/04/2019] [Indexed: 12/22/2022] Open
Abstract
Abstract
BACKGROUND
Y-stenting is an effective but challenging approach for wide-neck aneurysms. PulseRider (PR) (Pulsar/Cerenovus) is a new device designed to provide scaffolding during coiling but has never been compared with other techniques.
OBJECTIVE
To compare the immediate and 6-mo results of Y-stenting vs PR assisted coiling.
METHODS
A total of 105 consecutive patients were retrospectively divided into 2 groups (73 Y-stenting and 32 PR). All underwent angiographic 6-mo follow-up. We evaluated if some anatomical features could influence treatment results.
RESULTS
The groups were homogeneous. Immediate adequate occlusions as well as complication rates were similar in Y-stenting and PR group (94.5% vs 96.9% and 8.2% vs 6.2%, respectively). At 6 mo, adequate occlusion was 93.1% after Y-stenting and 84.3% after PR (P = .28), complete occlusion was significantly higher after Y-stenting: 90.3% vs 62.5% (P = .0017). Occlusion grade worsening occurred in 6.9% of Y-stenting and 18.7% of PR patients (P = .09).
Neck size was associated with occlusion grade in both groups. Maximal aneurysm size was associated with occlusion grade in the PR group (P = .023) but not in the Y-stenting group (P = .06). After PR, 6-mo occlusion rate was higher in small (< 10 mm) than in large aneurysms (P = .0094); this was not observed after Y-stenting (P = .54).
Location did not significantly affect the mid-term occlusion rate in both the groups. After PR, occlusion was more stable in basilar than anterior or middle cerebral artery aneurysms.
CONCLUSION
Y-stenting and PR are both effective with similar immediate and mid-term results. However, treatment stability seems higher after Y-stenting. Aneurysm size seems to negatively affect PR results.
Collapse
Affiliation(s)
- Nicola Limbucci
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Carlo Cirelli
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Iacopo Valente
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
- Radiology and Neuroradiology Unit, Catholic University of Sacred Heart, Agostino Gemelli University Polyclinic Foundation, Rome, Italy
| | - Sergio Nappini
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Leonardo Renieri
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Antonio Laiso
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Andrea Rosi
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Tommaso Amadori
- Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy
| | - Andrea Amadori
- Neuroanesthesiology and Intensive Care Unit, Careggi University Hospital, Florence, Italy
| | | |
Collapse
|
14
|
Bonanno L, Zulato E, Attili I, Pavan A, Del Bianco P, Nardo G, Boscolo Bragadin A, Pasqualini L, Calabrese F, Fassan M, Pasello G, Guarneri V, Amadori A, Conte P, Indraccolo S. Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz073.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Bonanno L, Zulato E, Attili I, Pavan A, Del Bianco P, Nardo G, Verza M, Pasqualini L, Pasello G, Zago G, Frega S, Fassan M, Calabrese F, Amadori A, Guarneri V, Conte P, Indraccolo S. Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Indraccolo S, Pinazza M, Ghisi M, Minuzzo S, Agnusdei V, Ciminale V, Pezzè L, Ciribilli Y, Amadori A. PO-114 Histone deacetylase 6 regulates NOTCH3 endosomal trafficking and degradation in T-cell acute lymphoblastic leukaemia cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
17
|
Volpi A, Savini S, Zoli W, Vasini M, Morgagni S, Amadori A, Volpi R, Amadori D. An Efficient Method for Culturing Human Breast Epithelium: Analysis of Results. Tumori 2018; 77:460-4. [PMID: 1803709 DOI: 10.1177/030089169107700602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We have examined the possibility of obtaining primary cultures from breast tissue utilizing a method especially developed for breast epithelium. The number of specimens able to grow in culture was very high: 82.8%, 64.3 %, 75.0 % and 77.8 %, respectively, for primary breast cancer, skin recurrences, inflammatory breast cancer and normal breast tissue. In our experience, growth was not related to menopausal status or histopathologic type, whereas for skin recurrences, a prior pharmacologic treatment (chemotherapy) of the patient enhanced the growth capacity of the tissue. This culture method could help to study the basic biology of breast epithelia and to improve the chemotherapy approach of breast cancer patients.
Collapse
Affiliation(s)
- A Volpi
- Morgagni-Pierantoni Hospital, Department of Oncology, Forlì, Italy
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Indraccolo S, Minuzzo S, Gola E, Habeler W, Carrozzino F, Noonan D, Albini A, Santi L, Amadori A, Chieco-Bianchi L. Generation of Expression Plasmids for Angiostatin, Endostatin and Timp-2 for Cancer Gene Therapy. Int J Biol Markers 2018; 14:251-6. [PMID: 10669955 DOI: 10.1177/172460089901400410] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated, and characterized in vitro. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer, and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 293T cells, followed by Western blotting (WB) or radioimmunoprecipitation analysis of both cell lysates and supernatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inhibitors.
Collapse
|
19
|
Guarneri V, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Cavazzini G, Garrone O, Bertone E, Cagossi K, Nanni O, Ferro A, Donadio M, Aieta M, Zamagni C, Piacentini F, Maiorana A, Ragazzi M, Cucchi MC, Querzoli P, Orsi N, Curtarello M, Urso L, Amadori A, Orvieto E, Vicini R, Balduzzi S, D'Amico R, Conte P. Abstract P1-13-02: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- V Guarneri
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - MV Dieci
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - G Bisagni
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - AA Brandes
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - A Frassoldati
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - L Cavanna
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - A Musolino
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - F Giotta
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - G Cavazzini
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - O Garrone
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - E Bertone
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - K Cagossi
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - O Nanni
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - A Ferro
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - M Donadio
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - M Aieta
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - C Zamagni
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - F Piacentini
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - A Maiorana
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - M Ragazzi
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - MC Cucchi
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - P Querzoli
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - N Orsi
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - M Curtarello
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - L Urso
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - A Amadori
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - E Orvieto
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - R Vicini
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - S Balduzzi
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - R D'Amico
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| | - P Conte
- University of Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; IRCCS AO S.Maria Nuova, Reggio Emilia, Italy; UOC Medical Oncology, AUSL Bologna, Bologna, Italy; Ferrara University Hospital, Ferrara, Italy; Guglielmo da Saliceto Hospital, Piacenza, Italy; University Hospital of Parma, Parma, Italy; National Cancer Research Centre Giovanni Paolo II, Bari, Italy; Azienda Ospedaliera Carlo Poma, Mantova, Italy; S. Croce and Carle Teaching Hospital, Cuneo, Italy; S.Anna Hospital, Torino, Italy; Ramazzini Hospital, Carpi, Italy; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; AOU Città della Salute e della Scienza, Torino, Italy; IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; S. Orsola-Malpighi Hospital, Bologna, Italy; Modena University Hospital, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy; Anatomic Pa
| |
Collapse
|
20
|
Navaglia F, Fogar P, Greco E, Basso D, Stefani AL, Mazza S, Zambon CF, Habeler W, Altavilla G, Amadori A, Cecchetto A, Plebani M. CD44v10: An Antimetastatic Membrane Glycoprotein for Pancreatic Cancer. Int J Biol Markers 2018; 18:130-8. [PMID: 12841682 DOI: 10.1177/172460080301800206] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims The aims of this study were 1) to investigate the mRNA pattern of CD44 variants in three primary (MIA PaCa 2, PANC-1, PSN-1) and two metastatic (CAPAN-1, SUIT-2) pancreatic cancer (PC) cell lines; 2) to ascertain whether the genetic transfer of CD44s and CD44v10 modifies the adhesion of PC cells to the extracellular matrix (ECM) in vitro and their metastatic behavior in vivo. Methods CD44 mRNA analysis was done by means of RT-PCR. Adhesion to ECM the was assessed using coated microtiter plates. For the study of CD44v10 insertion in the CAPAN-1 line, liposome-mediated DNA transfer was used. SCID mice were employed for in vivo experiments. Results CD44v10 mRNA was not expressed by the CAPAN-1 nor by four of the six SUIT-2-derived clones. The stable expression of CD44v10 by modified CAPAN-1 significantly enhanced fibronectin adhesion. Mice without either liver or pancreatic metastases were more frequently found among the animals injected with modified (CD44v10 expressing) than with non-modified CAPAN-1. Conclusions 1) It is possible to differentiate between metastatic and non-metastatic PC cells on the basis of CD44v10 expression; 2) CD44v10 seems to be involved in mediating fibronectin adhesion in vitro and in counteracting metastases in vivo.
Collapse
Affiliation(s)
- F Navaglia
- Department of Laboratory Medicine, University of Padua, Padua, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Castioni CA, Amadori A, Bilotta F, Bolzon M, Barboni E, Caricato A, Dall'acqua G, DI Paola F, Forastieri Molinari A, Gritti P, LA Rosa I, Longo M, Maglione C, Martorano P, Munari M, Perotti V, Rasulo F, Ruggiero M, Santoro A, Scudeller L, Tumolo M, Mazzeo AT. Italian COnsensus in Neuroradiological Anesthesia (ICONA). Minerva Anestesiol 2017; 83:956-971. [PMID: 28492296 DOI: 10.23736/s0375-9393.17.11753-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Anesthetic management of patients undergoing endovascular procedures for treating intracranial aneurysms or cerebrovascular malformations must consider a number of specific challenges, in addition to those associated with anesthesia for other specialties. In addition to maintenance of physiological stability, manipulation of systemic and cerebral hemodynamic parameters may be required to treat any sudden unexpected catastrophic neurological events. A multidisciplinary group including neuro- and pediatric anesthesiologists, interventional neuroradiologists, neurosurgeons, and a clinical methodologist contributed to this document. This consensus working group from 21 Italian institutions identified open questions regarding the best practices for management of anesthesia during endovascular neuroradiological procedures for intracranial aneurysms and cerebrovascular malformations, and addressed these by formulating practical consensus statements. At the first meeting in November 2015, nine key areas were identified regarding choice of anesthetic, patient monitoring, hemodynamic targets, postoperative care, and the management of neuromuscular blockade, anticoagulant and/or antiplatelet therapy, and special considerations for pediatric patients. Nine subgroups were established and a medical librarian performed literature searches in the Cochrane and MEDLINE/PubMed databases for each group. Groups drafted literature summaries and provisional responses in the form of candidate consensus statements based on evidence, when possible, and clinical experience, when this was lacking. Final wording was agreed at a meeting in April 2016 and where possible evidence was graded using United States Preventive Services Task Force criteria. Consensus (defined as >90% agreement) was based on evidence, clinical experience, clinician preference, feasibility in the Italian healthcare system, and cost/benefit considerations.
Collapse
Affiliation(s)
- Carlo A Castioni
- Anesthesia and Critical Care Medicine 2, San Giovanni Bosco Hospital, Turin, Italy -
| | - Andrea Amadori
- Neuro-Anesthesiology and Intensive Care Unit, CTO Careggi University Hospital, Florence, Italy
| | - Federico Bilotta
- Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Moreno Bolzon
- Neuro-Intensive and Neuro-Anesthesiology Care Unit, Department of Neuroscience, Niguarda Hospital, Milan, Italy
| | - Edoardo Barboni
- Department of Neuroscience, Anesthesia and Intensive Care Unit, University of Marche, Ancona, Italy
| | - Anselmo Caricato
- Intensive Care Unit, Department of Anesthesiology and Intensive Care Medicine, "A. Gemelli" Teaching Hospital, Sacro Cuore Catholic University, Rome, Italy
| | - Guido Dall'acqua
- Unit of Neuroradiology, Department of Clinical Radiology, Azienda ULSS 9 Treviso, Treviso, Italy
| | - Francesco DI Paola
- Unit of Neuroradiology, Department of Clinical Radiology, Azienda ULSS 9 Treviso, Treviso, Italy
| | - Andrea Forastieri Molinari
- Emergency Department, Anesthesiology and Intensive Care Medicine, Intensive Care Unit, A. Manzoni Hospital, Lecco, Italy
| | - Paolo Gritti
- Department of Anesthesia and Intensive Care, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - Italia LA Rosa
- Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Marcello Longo
- Unit of Neuroradiology, "G. Martino" University Hospital, Messina, Italy
| | - Carla Maglione
- Postoperative Intensive Care Unit, Department of Anesthesia, Burn Center and Hyperbaric Center, Antonio Cardarelli Hospital, Naples, Italy
| | - Pietro Martorano
- Unit of Neuro-Anesthesia, Emergency Department, "Ospedali Riuniti" Marche University Hospital, Ancona, Italy
| | - Marina Munari
- Unit of Neuro-Intensive and Neuro-Anesthesiology Care, Department of Anesthesia and Intensive Care Medicine, Padua University Hospital, University of Padua, Padua, Italy
| | - Valerio Perotti
- Section of Anesthesia in Speciality Surgeries, Department of Emergency and Internal Medicine, Policlinico Universitario Agostino Gemelli, Sacro Cuore Catholic University, Rome, Italy
| | - Frank Rasulo
- Department of Anesthesia, Critical Care and Emergency Medicine, Spedali Civili University Hospital, Brescia, Italy
| | - Maria Ruggiero
- Department of Neuroradiology, AUSL Romagna, Cesena, Italy
| | - Antonio Santoro
- Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Luigia Scudeller
- Clinical Epidemiology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | - Miriam Tumolo
- Department of Anaesthesia and Intensive Care, Giannina Gaslini Children's Hospital, Genoa, Italy
| | - Anna T Mazzeo
- Unit of Anesthesia and Intensive Care, Department of Surgical Sciences, University of Turin, Turin, Italy
| | | |
Collapse
|
22
|
Tosello V, Bordin F, Yu J, Agnusdei V, Indraccolo S, Basso G, Amadori A, Piovan E. Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation. Leukemia 2015; 30:812-22. [PMID: 26648536 DOI: 10.1038/leu.2015.335] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 11/20/2015] [Accepted: 11/24/2015] [Indexed: 12/26/2022]
Abstract
The calcineurin (Cn)-nuclear factor of activated T cells signaling pathway is critically involved in many aspects of normal T-cell physiology; however, its direct implication in leukemogenesis is still ill-defined. Glycogen synthase kinase-3β (GSK-3β) has recently been reported to interact with Cn in neuronal cells and is implicated in MLL leukemia. Our biochemical studies clearly demonstrated that Cn was able to interact with GSK-3β in T-cell acute lymphoblastic leukemia (T-ALL) cells, and that this interaction was direct, leading to an increased catalytic activity of GSK-3β, possibly through autophosphorylation of Y216. Sensitivity to GSK-3 inhibitor treatment correlated with altered GSK-3β phosphorylation and was more prominent in T-ALL with Pre/Pro immunophenotype. In addition, dual Cn and GSK-3 inhibitor treatment in T-ALL cells promoted sensitization to apoptosis through proteasomal degradation of X-linked inhibitor of apoptosis protein (XIAP). Consistently, resistance to drug treatments in primary samples was strongly associated with higher XIAP protein levels. Finally, we showed that dual Cn and GSK-3 inhibitor treatment in vitro and in vivo is effective against available models of T-ALL, indicating an insofar untapped therapeutic opportunity.
Collapse
Affiliation(s)
- V Tosello
- UOC Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - F Bordin
- Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Universita' di Padova, Padova, Italy
| | - J Yu
- Department of Biomedical Informatics, Columbia University, New York, NY, USA.,Department of Systems Biology, Columbia University, New York, NY, USA
| | - V Agnusdei
- UOC Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - S Indraccolo
- UOC Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - G Basso
- Dipartimento di Salute della Donna e del Bambino, Università di Padova, Padova, Italy
| | - A Amadori
- UOC Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.,Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Universita' di Padova, Padova, Italy
| | - E Piovan
- UOC Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.,Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Universita' di Padova, Padova, Italy
| |
Collapse
|
23
|
Rumiato E, Brunello A, Ahcene-Djaballah S, Borgato L, Gusella M, Menon D, Pasini F, Amadori A, Saggioro D, Zagonel V. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study. Pharmacogenomics J 2015; 16:525-529. [PMID: 26503812 DOI: 10.1038/tpj.2015.73] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 08/27/2015] [Accepted: 09/08/2015] [Indexed: 11/09/2022]
Abstract
So far, no reliable predictive clinicopathological markers of response to aromatase inhibitors (AIs) have been identified, and little is known regarding the role played by host genetics. To identify constitutive predictive markers, an array-based association study was performed in a cohort of 55 elderly hormone-dependent breast cancer (BC) patients treated with third-generation AIs. The array used in this study interrogates variants in 225 drug metabolism and disposition genes with documented functional significance. Six variants emerged as associated with response to AIs: three located in ABCG1, UGT2A1, SLCO3A1 with a good response, two in SLCO3A1 and one in ABCC4 with a poor response. Variants in the AI target CYP19A1 resulted associated with a favourable response only as haplotype; haplotypes with increased response association were also detected for ABCG1 and SLCO3A1. These results highlight the relevance of host genetics in the response to AIs and represent a first step toward precision medicine for elderly BC patients.
Collapse
Affiliation(s)
- E Rumiato
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - A Brunello
- Medical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - S Ahcene-Djaballah
- Medical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - L Borgato
- Hemato-Oncology Unit, Medical Science Department ULSS 13, Mirano, Venezia, Italy
| | - M Gusella
- Division of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy
| | - D Menon
- Division of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy
| | - F Pasini
- Division of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy
| | - A Amadori
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.,Department of Surgery, Oncology, and Gastroenterology, Oncology Section, University of Padova, Padova, Italy
| | - D Saggioro
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - V Zagonel
- Medical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| |
Collapse
|
24
|
Titti F, Sernicola L, Corrias F, Borsetti A, Maggiorella MT, Panzini G, Geraci A, Zamarchi R, Amadori A, Chieco-Bianchi L, Verani P. Vaccination of cynomolgus monkeys with whole inactivated or live-attenuated simian immunodeficiency virus. Antibiot Chemother (1971) 2015; 48:131-8. [PMID: 8726516 DOI: 10.1159/000425168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- F Titti
- Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Faulkner-Valle GP, De Rossi A, Dalla Gassa O, Francavilla E, Amadori A, Chieco-Bianchi L. Human retrovirus infection and immunodeficiencies. Detection and significance of virus-neutralizing antibodies. Antibiot Chemother (1971) 2015; 38:159-66. [PMID: 3662468 DOI: 10.1159/000414230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
26
|
Brandes AA, Franceschi E, Ermani M, Tosoni A, Albani F, Depenni R, Faedi M, Pisanello A, Crisi G, Urbini B, Dazzi C, Cavanna L, Mucciarini C, Pasini G, Bartolini S, Marucci G, Morandi L, Zunarelli E, Cerasoli S, Gardini G, Lanza G, Silini EM, Cavuto S, Baruzzi A, Baruzzi A, Albani F, Calbucci F, D'Alessandro R, Michelucci R, Brandes A, Eusebi V, Ceruti S, Fainardi E, Tamarozzi R, Emiliani E, Cavallo M, Franceschi E, Tosoni A, Cavallo M, Fiorica F, Valentini A, Depenni R, Mucciarini C, Crisi G, Sasso E, Biasini C, Cavanna L, Guidetti D, Marcello N, Pisanello A, Cremonini AM, Guiducci G, de Pasqua S, Testoni S, Agati R, Ambrosetto G, Bacci A, Baldin E, Baldrati A, Barbieri E, Bartolini S, Bellavista E, Bisulli F, Bonora E, Bunkheila F, Carelli V, Crisci M, Dall'Occa P, de Biase D, Ferro S, Franceschi C, Frezza G, Grasso V, Leonardi M, Marucci G, Mazzocchi V, Morandi L, Mostacci B, Palandri G, Pasini E, Pastore Trossello M, Pession A, Ragazzi M, Riguzzi P, Rinaldi R, Rizzi S, Romeo G, Spagnolli F, Tinuper P, Trocino C, Cerasoli S, Dall'Agata M, Faedi M, Frattarelli M, Gentili G, Giovannini A, Iorio P, Pasquini U, Galletti G, Guidi C, Neri W, Patuelli A, Strumia S, Casmiro M, Gamboni A, Rasi F, Cruciani G, Cenni P, Dazzi C, Guidi A, Zumaglini F, Amadori A, Pasini G, Pasquinelli M, Pasquini E, Polselli A, Ravasio A, Viti B, Sintini M, Ariatti A, Bertolini F, Bigliardi G, Carpeggiani P, Cavalleri F, Meletti S, Nichelli P, Pettorelli E, Pinna G, Zunarelli E, Artioli F, Bernardini I, Costa M, Greco G, Guerzoni R, Stucchi C, Iaccarino C, Rizzi R, Zuccoli G, Api P, Cartei F, Fallica E, Granieri E, Latini F, Lelli G, Monetti C, Ramponi V, Saletti A, Schivalocchi R, Seraceni S, Tola MR, Urbini B, Giorgi C, Montanari E, Cerasti D, Crafa P, Dascola I, Florindo I, Mazza S, Servadei F, Silini E, Torelli P, Immovilli P, Morelli N, Vanzo C. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract 2014; 1:166-171. [PMID: 26034628 PMCID: PMC4369716 DOI: 10.1093/nop/npu021] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2014] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome of glioblastoma (GBM) or the diffusion and impact of the current standard therapeutic approach in newly diagnosed patients younger than aged 70 years. METHODS Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). Based on the data from this registry, a prospective evaluation was made of the treatment efficacy and outcome in GBM patients. RESULTS Two hundred sixty-seven GBM patients (median age, 64 y; range, 29-84 y) were enrolled. The median overall survival (OS) was 10.7 months (95% CI, 9.2-12.4). The 139 patients ≤aged 70 years who were given standard temozolomide treatment concomitant with and adjuvant to radiotherapy had a median OS of 16.4 months (95% CI, 14.0-18.5). With multivariate analysis, OS correlated significantly with KPS (HR = 0.458; 95% CI, 0.248-0.847; P = .0127), MGMT methylation status (HR = 0.612; 95% CI, 0.388-0.966; P = .0350), and treatment received in a high versus low-volume center (HR = 0.56; 95% CI, 0.328-0.986; P = .0446). CONCLUSIONS The median OS following standard temozolomide treatment concurrent with and adjuvant to radiotherapy given to (72.8% of) patients aged ≤70 years is consistent with findings reported from randomized phase III trials. The volume and expertise of the treatment center should be further investigated as a prognostic factor.
Collapse
Affiliation(s)
- Alba A Brandes
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Enrico Franceschi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Mario Ermani
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Alicia Tosoni
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Fiorenzo Albani
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Roberta Depenni
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Marina Faedi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Anna Pisanello
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Girolamo Crisi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Benedetta Urbini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Claudio Dazzi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Luigi Cavanna
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Claudia Mucciarini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Giuseppe Pasini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Stefania Bartolini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Gianluca Marucci
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Luca Morandi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Elena Zunarelli
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Serenella Cerasoli
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Giorgio Gardini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Giovanni Lanza
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Enrico Maria Silini
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Silvio Cavuto
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | - Agostino Baruzzi
- Department of Medical Oncology , Bellaria - Maggiore Hospital, IRCCS Institute of Neurological Science , Bologna , Italy (A.A.B., E.F., A.T., S.B.); Department of Neurosciences, Statistics and Informatics Unit , Azienda Ospedale-Università , Padova , Italy (M.E.); IRCCS Institute of Neurological Sciences , Bologna , Italy (F.A., A.B.); Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy (F.A., A.B.); Department of Oncology, Hematology and Respiratory Diseases , University Hospital of Modena , Modena , Italy (R.D.); Department of Oncology and Hematology , Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS Cesena , Italy (M.F.); Neurology Unit, IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (A.P.); Department of Neuroradiology , University Hospital of Parma , Parma , Italy (G.C.); Clinical Oncology Unit , St Anna University Hospital , Ferrara , Italy (B.U.); Department of Oncology and Hematology , General Hospital , Ravenna , Italy (C.D.); Department of Oncology and Hematology, Oncology Unit , Azienda Ospedaliera Guglielmo da Saliceto , Piacenza , Italy (L.C.); Medical Oncology Unit , Ramazzini Hospital , Carpi , Italy (C.M.); Department of Medical Oncology , Infermi Hospital , Rimini , Italy (G.P.); Department of Biomedical and NeuroMotor Sciences (DiBiNeM) , University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital , Bologna , Italy (G.M., L.M.); Department of Pathology , Azienda Ospedaliero-Universitaria, Policlinico , Modena , Italy (E.Z.); Department of Human Pathology , AUSL Cesena Bufalini Hospital , Cesena , Italy (S.C.); Department of Pathology , IRCCS Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (G.G.); Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale , Sezione di Anatomia Patologica e Diagnostica Biomolecolare, Università di Ferrara , Ferrara , Italy (G.L.); Pathology Unit , Azienda Ospedaliero-Universitaria , Parma , Italy (E.M.S.); Department "Infrastructure Research and Statistics," IRCCS-Arcispedale Santa Maria Nuova , Reggio Emilia , Italy (S.C.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Rumiato E, Brunello A, Ahcene-Djaballah S, Borgato L, Gusella M, Pasini F, Fiduccia P, Amadori A, Zagonel V, Saggioro D. 651: An array-based pharmacogenetic study on elderly patients with advanced breast cancer treated with aromatase inhibitors. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50571-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Boldrin E, Rumiato E, Fassan M, Rugge M, Cagol M, Chiarion-Sileni V, Ruol A, Gusella M, Amadori A, Saggioro D. 948: Genetic variants of susceptibility in second primary esophageal cancer patients. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50840-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol 2013; 45:181-182. [PMID: 24129047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Indexed: 06/02/2023]
Abstract
Multiple sclerosis is a disease with a potentially severe prognosis and epidemiologically increasing. Interferon beta 1a is a very useful maintenance therapy widely used by neurologists. In the literature, there are several case reports of hypersensitivity reactions. In this case report we describe an anaphylactic IgE mediated reaction to interferon beta 1a. We also describe, for the first time in the medical literature, the non-irritating concentration (NIC) to be used for skin tests.
Collapse
|
30
|
Mandato VD, Abrate M, De Iaco P, Pirillo D, Ciarlini G, Leoni M, Comerci G, Ventura A, Lenzi B, Amadori A, Rosati F, Martinello R, De Palma R, Ventura C, Belotti LMB, Formisano D, La Sala GB. Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management. J Ovarian Res 2013; 6:19. [PMID: 23547941 PMCID: PMC3623733 DOI: 10.1186/1757-2215-6-19] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Accepted: 03/20/2013] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several hospitals throughout the region provide primary treatment for these patients and it is well know that treatment quality is correlated to the hospital that delivers. The aim of this study was to investigate the management and treatment of EOC in a Region of the North Italy (Emilia-Romagna, Italy). METHODS A multidisciplinary group made up of 11 physicians and 3 biostatisticians was formed in 2009 to perform clinical audits in order to identify quality indicators and to develop Region-wide workup in accordance with the principles of evidence-based medicine (EBM). The rationale was that, by setting up an oncogynecology network so as to achieve the best clinical practice, critical points would decrease or even be eliminated. Analysis of cases was based on the review of the medical records. RESULTS 614 EOC patients treated between 2007 and 2008 were identified. We found only 2 high-volume hospitals (≥ 21 patients/year), 3 medium-volume hospitals (11-20 operated patients/year), and 7 low-volume hospitals (≤ 10 operated patients /year). Only 222 patients (76.3%) had a histological diagnosis, FIGO surgical staging was reported only in 206 patients (70.9%) but not all standard surgical procedures were always performed, residual disease were not reported in all patients. No standard number of neoadjuvant chemotherapy cycles was observed. CONCLUSIONS The differences in terms of treatments provided led the multidisciplinary group to identify reference centers, to promote centralization, to ensure uniform and adequate treatment to patients treated in regional centers and to promote a new audit involving all regional hospitals to a complete review of the all the EOC patients.
Collapse
Affiliation(s)
- Vincenzo Dario Mandato
- Department of Obstetrics and Gynecology, Arcispedale S. Maria Nuova- IRCCS, Reggio Emilia, Italy
| | - Martino Abrate
- Department of Obstetrics and Gynecology, Arcispedale S. Maria Nuova- IRCCS, Reggio Emilia, Italy
| | - Pierandrea De Iaco
- Department of Obstetrics and Gynecology, University Hospital S. Orsola Malpighi, Bologna, Italy
| | - Debora Pirillo
- Department of Obstetrics and Gynecology, Arcispedale S. Maria Nuova- IRCCS, Reggio Emilia, Italy
| | - Gino Ciarlini
- Department of Obstetrics and Gynecology, Arcispedale S. Maria Nuova- IRCCS, Reggio Emilia, Italy
| | - Maurizio Leoni
- Oncology and Gynecology Unit, Ospedale Civile, Ravenna, Italy
| | | | - Alessandro Ventura
- Department of Obstetrics and Gynecology, Ospedale Civile, Guastalla, Reggio Emilia, Italy
| | - Bruno Lenzi
- Unit of Medicine, Hospital of Argenta, Ferrara, Italy
| | - Andrea Amadori
- Unit of Obstetrics and Gynecology, Ospedale G.B. Morgagni-L.Pierantoni, Forlì, Italy
| | - Federica Rosati
- Unit of Obstetrics and Gynecology, Ospedale degli Infermi, Rimini, Italy
| | - Ruby Martinello
- Unit of Obstetrics and Gynecology, University Hospital S. Anna, Ferrara, Italy
| | - Rossana De Palma
- Clinical Area Government, Health and Social Agency of Emilia-Romagna, Emilia-Romagna, Italy
| | - Chiara Ventura
- Clinical Area Government, Health and Social Agency of Emilia-Romagna, Emilia-Romagna, Italy
| | | | - Debora Formisano
- Statistics and Clinical Epidemiology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
| | - Giovanni Battista La Sala
- Department of Obstetrics and Gynecology, Arcispedale S. Maria Nuova- IRCCS; University of Modena and Reggio Emilia, Reggio Emilia, Italy
| |
Collapse
|
31
|
Fedrigo M, Poli F, Esposito G, Feltrin G, Toscano G, d'Agostino C, Schiavon B, Gerosa G, Amadori A, Valente M, Thiene G, Angelini A. HLA-DRB1 typing by micro-bead array assay identifies the origin of early lymphoproliferative disorder in a heart transplant recipient. Am J Transplant 2013; 13:802-7. [PMID: 23331771 DOI: 10.1111/ajt.12063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 11/01/2012] [Accepted: 11/19/2012] [Indexed: 01/25/2023]
Abstract
We report the case of a 68-year-old woman who underwent heart transplantation for hypertrophic cardiomyopathy. Two months after the transplant she developed mild fever and dyspnea with a marked drop in left ventricle ejection fraction of 31%. Coronary angiography was negative for cardiac allograft vasculopathy. Endomyocardial biopsy revealed ischemic damage with no evidence of acute cellular rejection, antibody-mediated rejection or viral myocarditis. A neoplastic process was suspected even though full-body computerized tomography was negative for malignancy. The patient died 4 months after transplantation. The autopsy showed acute antero-septal myocardial infarction due to a nodular epicardial EBV-related posttransplant lymphoproliferative disorder (PTLD) infiltrating the left anterior descending coronary artery with occlusive neoplastic thrombosis. We highlight two major aspects of this case: (1) the unusual occurrence of early PTLD involving the cardiac allograft and causing a fatal outcome, (2) the application of an immunological technique for HLA-DRB1 typing to posttransplant paraffin-embedded autopsy material to identify the recipient origin of this early malignancy, thus excluding a possible donor-transmitted neoplasm.
Collapse
Affiliation(s)
- M Fedrigo
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Amantini A, Carrai R, Lori S, Peris A, Amadori A, Pinto F, Grippo A. Neurophysiological monitoring in adult and pediatric intensive care. Minerva Anestesiol 2012; 78:1067-1075. [PMID: 22672930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Clinical neurophysiology is both an extension of clinical examination and an integration of neuroimaging. It plays a role in diagnosis, prognosis and monitoring in the Intensive Care Unit (ICU). Electroencephalography (EEG) and somatosensory evoked potentials (SEPs) are the most informative neurophysiological tests. Both have a major prognostic role in the hypoxic-ischemic encephalopathy and traumatic brain injury (TBI). In the former the absence of bilateral cortical SEPs has an unfavorable prognostic significance of 100%, whereas bilateral normal SEPs has uncertain prognostic value. In TBI these SEP patterns have high early prognostic value for both bad and good outcome. Continuous EEG monitoring is indicated for diagnosis and treatment of non convulsive seizures and status epilepticus (NCSE), whereas SEPs are more able to indicate the occurrence of neurological deterioration. In our opinion EEG-SEP monitoring is also valuable for interpretation and management of ICP trends, contributing to optimise treatment in a single patient. The EEG seems to have the same prognostic utility in pediatric as in adult ICU. Recent reviews supported the use of SEPs in the integrated process of outcome prediction after acute brain injury in children. However differences in interpretation are needed and the issue is whether it is possible to establish an age limit over which the prediction of SEPs is similar to that in adults. There are only a few studies of seizure prevalence in pediatric ICU. The variability of frequency of NCSE in comatose children is high as in adults and, similar to the adult, remains unclear the impact on outcome.
Collapse
Affiliation(s)
- A Amantini
- Clinical Neurophysiology, Neuroscience Department, Careggi Teaching Hospital, Florence, Italy.
| | | | | | | | | | | | | |
Collapse
|
33
|
Rumiato E, Cavallin F, Cagol M, Alfieri R, Ruol A, Ancona E, Amadori A, Saggioro D. 941 Genetic Polymorphisms as Predictive/prognostic Biomarkers in Esophageal Cancer Patients Receiving Cisplatin/5-Fluorouracil-based Neoadjuvant Chemotherapy. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71562-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Sturchio E, Amadori A, Businaro J, Ficociello B, Ferrazza P, Colosio C, Minoia C. [Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos]. G Ital Med Lav Ergon 2012; 34:571-573. [PMID: 23405719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Exposure to asbestos is the predominant cause of pleural mesothelioma (PM). The PM is a tumor difficult to diagnose, chemoresistant, and with rising Incidence. The long latency periods and the lack of preventive and therapeutic strategies for the MP, suggest that asbestos will be a social and health issue in the near future. Therefore, this overview focuses on current knowledge of epigenetic alterations and on the key role of microRNAs, small RNAs that negatively regulate gene expression, as biomarkers in PM development. Dysregulated microRNA expression pattern is specific for different cancers, including MP. MicroRNA expression analysis is a promising tool for diagnosis, typing of MP than normal tissue and other lung tumors and monitoring of new therapies. However, a better knowledge of miRNA signatures in PM is still necessary to verify the contribution of specific miRNAs as diagnostic biomarkers, also compared to different asbestos forms, exposure and subject work history.
Collapse
Affiliation(s)
- E Sturchio
- NAIL Settore Ricerca, Certificazione e Verifica - DIPIA, Via Urbana 167, 00184 Roma.
| | | | | | | | | | | | | |
Collapse
|
35
|
Rumiato E, Pasello G, De Salvo G, Parenti A, Cagol M, Ruol A, Ancona E, Amadori A, Saggioro D. 774 Copy Number Profile of Esophageal Cancer – Comparative Analysis of Adenocarcinoma and Squamous Cell Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71410-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Bravaccini S, Amadori A, Scarpi E, Tumedei MM, Zoli W, Silvestrini R. Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN. Anal Cell Pathol (Amst) 2012; 35:377-80. [PMID: 22596181 PMCID: PMC4605540 DOI: 10.3233/acp-2012-0066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Telomerase, a fundamental marker of neoplastic transformation, is widely expressed in both premalignant intraepithelial lesions and in most malignant lesions of the uterine cervix. We determined telomerase activity (TA) in uterine cervix by Repeat Amplification Protocol (TRAP) in a series of 62 cases, 44 with benign diseases (inflammation and/or metaplasia and/or acanthosis) and 18 with cervical intraepithelial neoplasia (CIN). No significant differences in TA were observed between benign lesions (median AEU value 36, range 0–119) and CIN (median AEU value 30, range 0–65). Conversely, TA was significantly higher in subjects who showed CIN evolution (65 range 45–119) than in disease-free individuals (34 range 0–95, p = 0.017) and in 1 patient with a CIN2 lesion who relapsed after 5 years. Our results suggest that TA of the uterine cervix is capable of predicting CIN evolution or relapse, thus indicating its potential usefulness as a prognostic marker in clinical surveillance programs.
Collapse
Affiliation(s)
- Sara Bravaccini
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy.
| | | | | | | | | | | |
Collapse
|
37
|
Fossi S, Carrai R, Amadori A, Bucciardini L, Innocenti P, Cossu C, Gabbanini S, Lori S, Pinto F, Grippo A, Amantini A. P11.15 Continuous EEG-SEP monitoring of acute brain injury in neurointensive care unit. Clin Neurophysiol 2011. [DOI: 10.1016/s1388-2457(11)60403-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
38
|
Amantini A, Fossi S, Carrai R, Spalletti M, Amadori A, Bucciardini L, Innocenti P, Cossu C, Lanzo G, Pinto F, Grippo A. P12.1 Nonconvulsive status epilepticus in acute brain injury: a prospective continuous EEG study. Clin Neurophysiol 2011. [DOI: 10.1016/s1388-2457(11)60404-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Bertolin M, Pigozzo J, Koussis H, Ghiotto C, Valente S, Michieletto S, Magro C, Rossi E, Zamarchi R, Bozza F, Jirillo A, Chiarion-Sileni V, Amadori A. Circulating tumor cells detection and evaluation of their apoptotic status in patients with localized breast cancer before and after surgery. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V, Tosello V, Basso G, Amadori A, Indraccolo S. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011; 25:588-98. [PMID: 21263446 DOI: 10.1038/leu.2010.323] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Activation of the Notch pathway occurs commonly in T acute lymphoblastic leukemia (T-ALL) because of mutations in Notch1 or Fbw7 and is involved in the regulation of cell proliferation and survival. Deregulated Notch3 signalling has also been shown to promote leukemogenesis in transgenic mice, but the targets of Notch3 in human T-ALL cells remain poorly characterized. Here, we show that Notch3 controls levels of mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1). In a model of T-ALL cell dormancy, both Notch3 activation and MKP-1 expression were upregulated in aggressive compared with dormant tumors, and this inversely correlated with the levels of phosphorylated p38 and extracellular signal-regulated kinase1/2 (ERK1/2) MAPKs, two canonical MKP-1 targets. We demonstrate that MKP-1 protein levels are regulated by Notch3 in T-ALL cell lines because its silencing by RNA interference or treatment with γ-secretase inhibitors induced strong MKP-1 reduction whereas activation of Notch3 signalling had the opposite effect. Furthermore, MKP-1 has an important role in T-ALL cell survival because its attenuation by short hairpin RNA significantly increased cell death under stress conditions. This protective function has a key role in vivo, as MKP-1-deficient cells showed impaired tumorigenicity. These results elucidate a novel mechanism downstream of Notch3 that controls the survival of T-ALL cells.
Collapse
Affiliation(s)
- M Masiero
- Department of Oncology and Surgical Sciences, University of Padova, Padova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
|
43
|
Zovato S, Opocher G, Rossi E, Indraccolo S, Amadori A, Pastorelli D, Lombardi G, Anglani M, Zamarchi R. 7144 Predictive value and biologic significance of circulating tumor cells (CTC) in sporadic and von hippel lindau (VHL) renal cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71477-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
44
|
Basso U, Rossi E, Indraccolo S, Barile C, Sava T, Aieta M, Brunello A, Jirillo A, Amadori A, Zamarchi R. 7117 Do circulating tumor cells (CTCs) correlate with response to first-line sunitinib in metastatic renal carcinoma? EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71450-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
45
|
Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009; 76:375-86. [PMID: 19407470 DOI: 10.1159/000215581] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 01/26/2009] [Indexed: 11/19/2022]
Abstract
Breast cancer is the most common cancer in women. Although survival rates have improved with the use of new therapeutic agents, many issues remain unresolved and new predictive and prognostic factors are needed in clinical practice. Several studies have suggested a prognostic and predictive role for circulating and disseminated tumor cells in metastatic disease and adjuvant treatment. Because of recent technological advances, oncologists have gained a new perspective on this disease. Circulating tumor cells could be both a new tumor marker as well as a tool to gain novel insight into the natural history of this neoplastic disease.
Collapse
Affiliation(s)
- A Amadori
- Istituto Oncologico Veneto IRCCS, Padova, Italy
| | | | | | | | | | | |
Collapse
|
46
|
Amantini A, Fossi S, Grippo A, Innocenti P, Amadori A, Bucciardini L, Cossu C, Nardini C, Scarpelli S, Roma V, Pinto F. Continuous EEG-SEP monitoring in severe brain injury. Neurophysiol Clin 2009; 39:85-93. [PMID: 19467438 DOI: 10.1016/j.neucli.2009.01.006] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2008] [Revised: 01/07/2009] [Accepted: 01/18/2009] [Indexed: 02/06/2023] Open
Abstract
AIMS To monitor acute brain injury in the neurological intensive care unit (NICU), we used EEG and somatosensory evoked potentials (SEP) in combination to achieve more accuracy in detecting brain function deterioration. METHODS Sixty-eight patients (head trauma and intracranial hemorrhage; GCS<9) were monitored with continuous EEG-SEP and intracranial pressure monitoring (ICP). RESULTS Fifty-five patients were considered "stable" or improving, considering the GCS and CT scan: in this group, SEP didn't show significant changes. Thirteen patients showed neurological deteriorations and, in all patients, cortical SEP showed significant alterations (amplitude decrease>50% often till complete disappearance). SEP deterioration anticipated ICP increase in 30%, was contemporary in 38%, and followed ICP increase in 23%. Considering SEP and ICP in relation to clinical course, all patients but one with ICP less than 20 mmHg were stable, while the three patients with ICP greater than 40 mmHg all died. Among the 26 patients with ICP of 20-40 mmHg, 17 were stable, while nine showed clinical and neurophysiological deterioration. Thus, there is a range of ICP values (20-40 mmHg) were ICP is scarcely indicative of clinical deterioration, rather it is the SEP changes that identify brain function deterioration. Therefore, SEP have a twofold interest with respect to ICP: their changes can precede an ICP increase and they can constitute a complementary tool to interpret ICP trends. It has been very important to associate SEP and EEG: about 60% of our patients were deeply sedated and, because of their relative insensitivity to anesthetics, only SEP allowed us to monitor brain damage evolution when EEG was scarcely valuable. CONCLUSIONS We observed 3% of nonconvulsive status epilepticus compared to 18% of neurological deterioration. If the aim of neurophysiological monitoring is to "detect and protect", it may not be limited to detecting seizures, rather it should be able to identify brain deterioration, so we propose the combined monitoring of EEG with SEP.
Collapse
Affiliation(s)
- A Amantini
- Unit of Clinical Neurophysiology, DAI Neurological Sciences, University of Florence - Az., Ospedaliero Universitaria Careggi, V. le Morgagni 85, 50134 Florence, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Frosini C, Amadori A, Bucciardini L, Bacci I, Gandini E, Marinoni M, Mangiafico S, Innocenti P. Diagnosis and treatment of subarachnoid hemorrhage-induced vasospasm. Crit Care 2009. [PMCID: PMC4083988 DOI: 10.1186/cc7266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Berardi D, Tarricone I, Poggi F, Salvatori F, Morri M, Fini C, Amadori A. The Bologna multiethnic mental health centre. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Macor P, Piovan E, Zorzet S, Tripodo C, Marzari R, Amadori A, Tedesco F. Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab. Mol Immunol 2007. [DOI: 10.1016/j.molimm.2006.07.152] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Fossi S, Amantini A, Grippo A, Innocenti P, Amadori A, Bucciardini L, Cossu C, Scarpelli S, Bruni I, Sgalla R, Pinto F. Continuous EEG–SEP monitoring of severely brain injured patients in NICU: methods and feasibility. Neurophysiol Clin 2006; 36:195-205. [PMID: 17095409 DOI: 10.1016/j.neucli.2006.09.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
AIMS To evaluate the feasibility of a continuous neurophysiologic monitoring (electroencephalography (EEG)-somatosensory evoked potentials (SEPs)) in the neuro-intensive care unit (NICU), taking into account both the technical and medical aspects that are specific of this environment. METHODS We used an extension of the recording software that is routinely used in our unit of clinical neurophysiology. It performs cycles of alternate EEG and SEP recordings. Raw traces and trends are simultaneously displayed. Patient head and stimulator box are placed behind the bed and linked to the ICU monitoring terminal through optic fibers. The NICU staff has been trained to note directly clinical events, main artefacts and therapeutic changes. The hospital local area network (LAN) enables remote monitoring survey. RESULTS Continuous EEG (CEEG)-SEP monitoring was performed in 44 patients. Problems of needle detachment were seldomly encountered, thanks to the use of a sterile plastic dressing, which covers needles. We never had infection or skin lesions due to needles or the electrical stimulator. The frequent administration of sedative at high doses prevented us from having a clinically valuable EEG in several cases but SEPs were always monitorable, independently of the level of EEG suppression. The diagnosis of seizures and non-epileptic status was based on raw EEG, while quantitative EEG (QEEG) was used to quantify ictal activity as a guide to treatment. CONCLUSIONS EEG and EP waveforms collected in NICU were of comparable quality to routine clinical measurements and contained the same clinical information. A continuous SEP monitoring in a comatose and sedated patient in NICU is not technically more difficult and potentially less useful than in operating room. This monitoring appears to be feasible provided the observance of some requirement regarding setting, electrodes, montages, personnel integration, consulting and software.
Collapse
Affiliation(s)
- S Fossi
- UO Neurophysiopatology, Department of Neurological and Psychiatric Sciences, University of Florence, Azienda Ospedaliero-Universitaria Careggi, V.le Morgagni 85, 50134 Firenze, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|